ArticleBMC oral health2025
Do I-PRF adjuvant injections in TMJ arthrocentesis have a cumulative physiological effect? A retrospective cohort study.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of Platelet-Rich Fibrin for Temporomandibular Disorders Management: A Systematic and Meta-Analysis.Oral diseases · 2026Pooled it
- Use of liquid platelet-rich fibrin (liquid PRF) in temporomandibular joint disorders: A narrative review with clinical recommendations.Periodontology 2000 · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to compare the therapeutic outcomes of single versus multiple injectable platelet-rich fibrin (i-PRF) injections after arthrocentesis in patients with temporomandibular joint osteoarthritis (TMJ-OA). The objective was to evaluate and compare TMJ pain and mobility at the 1st, 6th, and 12th months postoperatively.
methodsThis retrospective cohort study included 85 female patients (age: 31-73 years, mean ± sd: 54.9 ± 8.8) who underwent arthrocentesis with i-PRF injections from June 2018 to November 2021, diagnosed with osteoarthritis based on the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD). Patients had no prior use of occlusal splint. During follow-up visits, pain was evaluated with a visual analog scale (pVAS) during function and maximum interincisal opening (MIO) was measured to assess jaw mobility. The study included patient follow-up records at four time points: preoperative (T0), 1 month postoperative (T1), 6 months postoperative (T2), and 12 months postoperative (T3). The primary outcome variable was pVAS at T3, secondary outcome variables were pVAS at T1 and T2, and MIO at T1, T2, and T3.
resultsNo significant differences were found in joint pain or mobility between groups at follow-ups (> 0.05).
conclusionsBoth groups showed similar outcomes in terms of pain and mobility over a 12-month period. Increasing the frequency of i-PRF injections does not appear to have an impact on therapeutic outcomes in patients with TMJOA. Given the retrospective design of this study, it is important to evaluate the results with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.